… treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based … treatment option for heavily pretreated patients with metastatic CRC.” Trial … U.S. FDA acceptance of New Drug Application for … : European Society for Medical Oncology Congress 2025; …

… treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based … advancement in a challenging treatment landscape, and if … Medical Oncology (ESMO) Annual Congress and published in The Lancet, the trial … U.S. FDA accepted the new drug application for …

… and Drug Administration (FDA) has accepted a new drug application … already received fluoropyrimidine-, oxaliplatin- and irinotecan-based … European Society for Medical Oncology Congress and … discuss emerging treatment options and trial opportunities with …

… with fluoropyrimidine-, oxaliplatin- and irinotecan-based … in a challenging treatment landscape, and … medicines and regimens at the forefront of cancer care. Powered by drug … KEYWORD: ONCOLOGY FDA HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: …

… fluorouracil, leucovorin, irinotecan, and oxaliplatin—has emerged as a potent … need for randomized controlled trials to validate efficacy and … disease challengespancreatic ductal adenocarcinoma treatmentPhase 1 clinical trial resultssurgical resection in …

… Therapy and Translational Medicine Molecular precision therapy … cancer patients treated with oxaliplatin. This observational study … inflammatory approach to sarcopenia. Pharmaceutics. 2022;14(3):648 … . Davis P. Novel drug treatments for pain in advanced …

… checkpoint blockers (ICB) and oxaliplatin (OXA));50 and ③ … dependence on specialized medical infrastructure.57 These … Nanotechnology-based drug delivery for breast cancer treatment: current … therapies using nanoplatforms. Pharmaceutics. 2025;17(3):306 …

… trial, patients were randomly assigned to receive either capecitabine (Xeloda) and oxaliplatin … noninferiority of 3 months of treatment (P = .0033). A … of 3 months of treatment was confirmed with CAPOX … ). “When deciding on treatment duration for high-risk stage …

… GEJ) cancers.  The European Medicines Agency’s (EMA’s … chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) as neoadjuvant … . Clinical Evidence and Trial Results  The positive … durvalumab as perioperative treatment for patients with resectable …

… heard the HERIZON-GEA-01 trial, where zanidatamab, which is … the first phase 3 trial in metastatic gastroesophageal adenocarcinoma … chemo in the upfront treatment of BRAF V600E-mutant … patients who had received an oxaliplatin-containing adjuvant regimen. I…